PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.05%
EBIT growth above 1.5x CRON.TO's 7.24%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
22.05%
Operating income growth at 75-90% of CRON.TO's 26.50%. Bill Ackman would demand a plan to enhance operating leverage.
22.04%
Net income growth at 75-90% of CRON.TO's 24.93%. Bill Ackman would press for improvements to catch or surpass competitor performance.
21.74%
EPS growth at 75-90% of CRON.TO's 25.00%. Bill Ackman would push for improved profitability or share repurchases to catch up.
21.74%
Diluted EPS growth at 75-90% of CRON.TO's 25.00%. Bill Ackman would expect further improvements in net income or share count reduction.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
93.50%
OCF growth 1.25-1.5x CRON.TO's 64.04%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
93.50%
FCF growth above 1.5x CRON.TO's 35.45%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-102.50%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-102.50%
Negative 5Y OCF/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-102.50%
Negative 3Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
73.12%
10Y net income/share CAGR of 73.12% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
73.12%
Net income/share CAGR of 73.12% while CRON.TO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
73.12%
3Y net income/share CAGR of 73.12% while CRON.TO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
-79.29%
Negative equity/share CAGR over 10 years while CRON.TO stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-79.29%
Negative 5Y equity/share growth while CRON.TO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-79.29%
Negative 3Y equity/share growth while CRON.TO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-60.53%
Firm’s AR is declining while CRON.TO shows 22.22%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
Negative asset growth while CRON.TO invests at 8.85%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-9.38%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
352.04%
We expand SG&A while CRON.TO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.